Recordati buys Orphan Europe for $191M

Italy's Recordati has agreed to acquire Orphan Europe for €135 million ($191 million). Orphan Europe is a Paris-based pharmaceutical group that specializes in rare diseases. The deal should close by the end of 2007. Orphan Europe currently markets ten products that target mostly chronic and life-threatening diseases.

"The acquisition of Orphan Europe fits well with Recordati's growth strategy based on expansion and the strengthening of its product portfolio and pipeline," noted Giovanni Recordati, Chairman and CEO. "Orphan Europe represents a unique opportunity to strengthen our R&D capabilities and to establish even closer relationships with academic researchers and eminent scientists."

- see the release from Recordati

Related Articles:
The EU's tips for a successful biotech sector. Report
NIH expert sees new drive against rare disease. Report
Progeria trial underscores challenge of rare diseases. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.